BAMF Health has announced the first phase I/IIa treatment for the investigational radiopharmaceutical therapy lutetium-177 (Lu-177) BetaBart.
The first dosing of a 51-year-old patient with metastatic lung cancer marks a milestone in the joint venture between the University of Texas MD Anderson Cancer Center and Radiopharm Theranostics, with BAMF Health serving as the radiopharmaceutical therapeutic trial center.
Lu-177 BetaBart is an engineered monoclonal antibody, designed with a strong affinity for the 4Ig isoform of B7-H3, an immune checkpoint molecule that is overexpressed across several tumor types, according to Radiopharm. Lu-177 BetaBart has the potential to become a highly differentiated radiotherapeutic for patients with aggressive advanced solid tumors, the company said.
